Abstract:Compounds with a phosphonate group, i.e., –P(O)(OH) 2 group attached directly to the molecule via a P-C bond serve as suitable non-hydrolyzable phosphate mimics in various biomedical applications. In principle, they often inhibit enzymes utilizing various phosphates as substrates. In this review we focus mainly on biologically active phosphonates that originated from our institute (Institute of Organic Chemistry and Biochemistry in Prague); i.e., acyclic nucleoside phosphonates (ANPs, e.g., adefovir, tenofovir, and cidofovir) and derivatives of non-nucleoside phosphonates such as 2-(phosphonomethyl) pentanedioic acid (2-PMPA). Principal strategies of their syntheses and modifications to prodrugs is reported. Besides clinically used ANP antivirals, a special attention is paid to new biologically active molecules with respect to emerging infections and arising resistance of many pathogens against standard treatments. These new structures include 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines or so-called "open-ring" derivatives, acyclic nucleoside phosphonates with 5-azacytosine as a base moiety, side-chain fluorinated ANPs, aza/deazapurine ANPs. When transformed into an appropriate prodrug by derivatizing their charged functionalities, all these compounds show promising potential to become drug candidates for the treatment of viral infections. ANP prodrugs with suitable pharmacokinetics include amino acid phosphoramidates, pivaloyloxymethyl (POM) and isopropoxycarbonyloxymethyl (POC) esters, alkyl and alkoxyalkyl esters, salicylic esters, (methyl-2-oxo-1,3-dioxol-4-yl) methyl (ODOL) esters and peptidomimetic prodrugs. We also focus on the story of cytostatics related to 9-[2-(phosphonomethoxy)ethyl]guanine and its prodrugs which eventually led to development of the veterinary drug rabacfosadine. Various new ANP structures are also currently investigated as antiparasitics, especially antimalarial agents e.g., guanine and hypoxanthine derivatives with 2-(phosphonoethoxy)ethyl moiety, their thia-analogues and N-branched derivatives. In addition to ANPs and their analogs, we also describe prodrugs of 2-(phosphonomethyl)pentanedioic acid (2-PMPA), a potent inhibitor of the enzyme glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA). Glutamate carboxypeptidase II inhibitors, including 2-PMPA have been found efficacious in various preclinical models of neurological disorders which are caused by glutamatergic excitotoxicity. Unfortunately its highly polar character and hence low bioavailability severely limits its potential for clinical use. To overcome this problem, various prodrug strategies have been used to mask carboxylates and/or phosphonate functionalities with pivaloyloxymethyl, POC, ODOL and alkyl esters. Chemistry and biological characterization led to identification of prodrugs with 44–80 fold greater oral bioavailability (tetra-ODOL-2-PMPA).

Lipophilic Nucleoside Triphosphate Prodrugs of Anti-HIV Active Nucleoside Analogs as Potential Antiviral Compounds

Membrane Permeable, Bioreversibly Modified Prodrugs of Nucleoside Diphosphate-γ-Phosphonates

Antiviral Activity of Lipophilic Nucleoside Tetraphosphate Compounds

Synthesis and Anti‐HIV Activity of a Series of 6‐modified 2′,3′‐dideoxyguanosine and 2′,3′‐didehydro‐2′,3′‐dideoxyguanosine Analogs

Intracellular Metabolism of Nucleoside/Nucleotide Analogues: a Bottleneck to Reach Active Drugs on HIV Reverse Transcriptase.

Synthesis and Antiviral Activities of Isonucleosides and Their Monophosphates

One-pot Synthesis of Nucleoside 5'-Triphosphates from Nucleoside 5'-H-phosphonates.

Novel Use of a Guanosine Prodrug Approach to Convert 2',3'-Didehydro-2',3'-dideoxyguanosine into a Viable Antiviral Agent.

Synthesis and spectroscopic analysis of 2′,3′-didehydro- 2′,3′-dideoxythymidine (d4T) 5′-thiophosphoramidates

Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones.

Phosphoramidate Protides of 2 '-C-methylguanosine As Highly Potent Inhibitors of Hepatitis C Virus. Study of Their in Vitro and in Vivo Properties

Synthesis And Biological Evaluation Of Novel 5-Alkyl-2-Arylthio-6-((3,4-Dihydroquinolin-1(2h)-Yl)Methyl)Pyrimidin-4(3 H)-Ones As Potent Non-Nucleoside Hiv-1 Reverse Transcriptase Inhibitors

Synthesis and Anti-Hiv Activity Evaluation of 1-[(Alkenyl or Alkynyl or Alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones As Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Synthesis of galactosyl phosphate diester derivatives of nucleosides

Synthesis and Evaluation of Anti-HIV Activity of Mono- and Di-Substituted Phosphonamidate Conjugates of Tenofovir

Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.

Structure-directed expansion of biphenyl-pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with significantly improved potency and safety

Hybrids of delavirdine and piperdin-4-yl-aminopyrimidines (DPAPYs) as potent HIV-1 NNRTIs: Design, synthesis and biological activities

Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.

Β-D-2′-c-methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates Are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5′-Triphosphate Forms

Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects